MiNK Therapeutics Future Growth

Future criteria checks 0/6

MiNK Therapeutics is forecast to grow earnings and revenue by 45.3% and 76.4% per annum respectively while EPS is expected to grow by 43.1% per annum.

Key information

45.3%

Earnings growth rate

43.1%

EPS growth rate

Biotechs earnings growth	28.5%
Revenue growth rate	76.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Nov 2024

Recent future growth updates

Recent updates

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Oct 26

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Jun 28

Earnings and Revenue Growth Forecasts

NasdaqCM:INKT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4	-29	-52	N/A	3
12/31/2025	N/A	-25	-51	N/A	4
12/31/2024	N/A	-10	-40	N/A	4
9/30/2024	N/A	-14	N/A	N/A	N/A
6/30/2024	N/A	-17	-12	-12	N/A
3/31/2024	N/A	-21	-14	-14	N/A
12/31/2023	N/A	-22	-16	-16	N/A
9/30/2023	N/A	-25	-17	-17	N/A
6/30/2023	N/A	-26	-19	-19	N/A
3/31/2023	N/A	-26	-19	-19	N/A
12/31/2022	N/A	-28	-19	-19	N/A
9/30/2022	N/A	-26	-16	-16	N/A
6/30/2022	N/A	-34	-14	-14	N/A
3/31/2022	N/A	-34	-13	-13	N/A
12/31/2021	N/A	-30	-13	-13	N/A
9/30/2021	N/A	-26	-13	-13	N/A
6/30/2021	N/A	-18	-12	-12	N/A
3/31/2021	N/A	-16	-11	-11	N/A
12/31/2020	N/A	-16	-8	-8	N/A
12/31/2019	1	-24	-15	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INKT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INKT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INKT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INKT is forecast to have no revenue next year.

High Growth Revenue: INKT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INKT's Return on Equity is forecast to be high in 3 years time

MiNK Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 20% to US$6.67

Price target increased by 12% to US$7.00

Price target decreased to US$7.75

Recent updates

Price target decreased by 20% to US$6.67

MiNK Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MiNK Therapeutics, Inc. Announces Data from Two Poster Presentations at Society for Immunotherapy of Cancer's 39th Annual Meeting in Houston, Texas

MiNK Therapeutics, Inc. Announces Appointment of Dr. Robert Kadlec to Board of Directors

MiNK Therapeutics, Inc. Appoints Marc Van Dijk as Scientific Advisory Board Member, Effective from November 15, 2024

Insufficient new directors

MiNK Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Value of Listed Securities

MiNK Therapeutics Provides Non-Compliance Update with the Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

New minor risk - Shareholder dilution

MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding

MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding

MiNK Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

MiNK Therapeutics, Inc. to Report Q4, 2023 Results on Mar 21, 2024

MiNK Therapeutics Receives Letter from Nasdaq Notifying the Company Failed to Comply with the $1 Minimum Bid Price

MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer

Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Mink’S Agent-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

MiNK Therapeutics, Inc. Announces Resignation of as Director

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Price target increased by 12% to US$7.00

Executive Chairman recently bought US$95k worth of stock

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

Price target decreased to US$7.75

Mink Therapeutics, Inc. Presents Clinical Data At Sitc 2022 Showcasing Inkt Cell Therapy Pipeline

MiNK Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 2500 Value Index

MiNK Therapeutics A Bargain For Potential Cell Therapies

We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

MiNK Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

MiNK Therapeutics, Inc. to Report Q4, 2021 Results on Mar 18, 2022

MiNK Therapeutics Announces Patients Dosed with Agent-797 iNKT Cell Therapy in Solid Tumor Cancers

High number of new directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies